Mitul Gandhi, MD
Hematology & Oncology · Manassas, VANPI 1639379308
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $5,365 of the $7,517 with a category attached, or 71.4%. 35 manufacturers reported payments, led by Pfizer at 28.0% of the total. 2025 is the largest year on record at $2,518, 6.4 times the $394 reported in 2019.
Across 79 payments — averaging $95.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$2K
- GSK$2K
- Johnson & Johnson$846
- Janssen Scientific Affairs, LLC$818
- F. Hoffmann-la Roche AG$370
- Novartis$207
- plus $1K from 29 others
Across 1,797 payments — averaging $3870.27 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Genentech, Inc.$1.9M
- AstraZeneca$859K
- AbbVie$737K
- Beigene, Ltd.$538K
- Epizyme, Inc.$498K
- Janssen Research & Development, LLC$462K
- plus $1.9M from 14 others
What the payments were for
- Consulting fees$5,36571%
- Speaking & faculty fees$3705%
- Food & beverage$1,57321%
- Education$2103%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 10 | $2,105 |
| GSK | 3 | $1,877 |
| Johnson & Johnson(2 entities) | 5 | $846 |
| Janssen Scientific Affairs, LLC | 1 | $818 |
| F. Hoffmann-la Roche AG | 1 | $370 |
| Novartis | 11 | $207 |
| Exelixis Inc. | 1 | $100 |
| Beigene USA, Inc. | 4 | $91 |
| Bioprotect Medical, Inc. | 1 | $85 |
| AstraZeneca | 2 | $79 |
| AbbVie | 2 | $66 |
| Merck | 4 | $65 |
| Incyte Corporation | 3 | $62 |
| Genmab U.S., Inc. | 2 | $61 |
| Gilead(2 entities) | 3 | $57 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $56 |
| Seagen Inc. | 3 | $54 |
| Servier Pharmaceuticals LLC | 2 | $48 |
| Eisai Inc. | 2 | $47 |
| Sanofi | 1 | $46 |
| Ipsen Biopharmaceuticals, Inc | 2 | $43 |
| Regeneron Healthcare Solutions, Inc. | 1 | $37 |
| Iovance Biotherapeutics, Inc. | 1 | $36 |
| Karyopharm Therapeutics Inc. | 1 | $27 |
| Rigel Pharmaceuticals, Inc. | 1 | $27 |
| Astellas Pharma US Inc | 1 | $25 |
| Bristol Myers Squibb | 1 | $24 |
| E.r. Squibb & Sons, L.L.C. | 1 | $23 |
| Beone Medicines USA, Inc. | 1 | $23 |
| Geron Corporation | 1 | $21 |
| Sun Pharmaceutical Industries Inc. | 1 | $20 |
| Medtronic | 1 | $19 |
| Genentech USA, Inc. | 1 | $19 |
| Blueprint Medicines Corporation | 1 | $18 |
| Bayer | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,517 in reported general payments places this provider in the 85th percentile of 293 hematology & oncology providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Lenalidomide | 78 | $1,196,784 |
| RevlimidLenalidomide | 41 | $731,793 |
| JakafiRuxolitinib Phosphate | 23 | $437,808 |
| VenclextaVenetoclax | 20 | $135,289 |
| Abiraterone Acetate | 25 | $89,258 |
| CalquenceAcalabrutinib Maleate | 11 | $80,028 |
| EliquisApixaban | 25 | $25,244 |
| XareltoRivaroxaban | 21 | $19,411 |
| Anastrozole | 100 | $1,980 |
| Acyclovir | 112 | $1,323 |
| Hydroxyurea | 60 | $1,123 |
| Letrozole | 17 | $671 |
| Tamoxifen Citrate | 13 | $621 |
| Dexamethasone | 36 | $392 |
| Prochlorperazine Maleate | 29 | $335 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bristol Myers SquibbRevlimid | $24 | $731,79341 claims |
| Incyte CorporationJakafi | $62 | $437,80823 claims |
| AbbVieVenclexta | $66 | $135,28920 claims |
| Janssen Scientific Affairs, LLCAbiraterone Acetate | $818 | $89,25825 claims |
| AstraZenecaCalquence | $79 | $80,02811 claims |
| PfizerEliquis | $2,105 | $25,24425 claims |
| Johnson & JohnsonXarelto | $846 | $19,41121 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 293 hematology & oncology providers in Virginia.
Other hematology & oncology in Manassas
- Ruby KochharHampton$236K
- Victor YazbeckRichmond$190K
- David ChangNewport News$141K
- William ErshlerFairfax$139K
- Yue ZhangVirginia Beach$105K
- Jerome GoldschmidtChristiansburg$105K
- Attique SamdaniRichmond$104K
- Gary SimmonsNorfolk$82K
- Mark FlemingHampton$71K
- Sekwon JangFairfax$56K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.